Avalo Therapeutics (AVTX) Other Non-Current Liabilities (2015 - 2026)

Avalo Therapeutics (AVTX) has 11 years of Other Non-Current Liabilities data on file, last reported at $35000.0 in Q4 2025.

• Quarterly Other Non-Current Liabilities fell 99.59% year-over-year to $35000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $35000.0 (down 99.59% YoY) and the FY2025 annual result came in at $35000.0, down 99.59% from the prior year.
• Other Non-Current Liabilities fell to $35000.0 in Q4 2025, from $23.2 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $23.2 million in Q3 2025 to a low of $35000.0 in Q4 2025.
• A 5-year average of $5.5 million and a median of $2.4 million in 2022 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Other Non-Current Liabilities soared 711.13% — and 2025, when it slumped 99.59%.
• Tracing AVTX's Other Non-Current Liabilities over 5 years: stood at $1.4 million in 2021, then soared by 245.99% to $4.8 million in 2022, then advanced by 14.91% to $5.6 million in 2023, then surged by 52.79% to $8.5 million in 2024, then tumbled by 99.59% to $35000.0 in 2025.
• The last three Other Non-Current Liabilities figures came in at $35000.0 (Q4 2025), $23.2 million (Q3 2025), and $10.3 million (Q2 2025), per Business Quant data.